Boehringer Ingelheim
Ipsen to acquire Sanofi assets in $88 million deal
February 13, 2017Sales and Marketing Boehringer Ingelheim, Prontalgine, Sanofi, ipsen
Ipsen has announced that it is set to enter into a definitive agreement to acquire five consumer healthcare products from …
Boehringer steps into Humira race with US and EU biosimilar filings
January 19, 2017Sales and Marketing Boehringer Ingelheim, Humira, biosimilar
Boehringer Ingelheim has just stepped into the ring to battle it out for a slice of Humira’s revenue with accepted …
Sanofi and Boehringer confirm successful exchange of businesses
January 3, 2017Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, Sanofi
Sanofi and Boehringer Ingelheim have confirmed the successful completion of the exchange of Sanofi’s animal health business (Merial, based in …
Five major pharma firms break ABPI code of conduct, according to watchdog
December 15, 2016Medical Communications, Sales and Marketing ABPI, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Grunenthal, Janssen
Eli Lilly, Boehgringer Ingelheim, AstraZeneca UK, Grunenthal and Janssen-Cilag have been “named and shamed” by the Prescription Medicines Code of …
FDA approves another indication for Lilly/Boehringer diabetes treatment
December 5, 2016Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, jardiance
Jardiance (empagliflozin), an oral SGLT02 inhibitor developed by Eli Lilly and distributed by Boehringer Ingelheim, has been approved by the …
Hanmi Pharmaceutical raided over insider trading suspicions
October 17, 2016Sales and Marketing Boehringer Ingelheim, Genentech, Hanmi Pharmaceutical, south korea
At the end of September, we reported on a busy 24-hour for Hanmi Pharmaceutical, as they secured a deal with …
Hanmi Pharma shares crash after shock contract termination
September 30, 2016Manufacturing and Production, Medical Communications, Research and Development Boehringer Ingelheim, Genentech, Germany, HM61713, Hanmi Pharmaceutical, Tagrisso, south korea
News broke on 29 September that Hanmi Pharma, South Korea’s leading drug maker, had signed a $910 million deal with …
Lilly, Boehringer Ingelheim to jointly study combination therapy for breast cancer
July 14, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, breast cancer, combination therapy, drug trial
US drug major Eli Lilly (NYSE: LLY) and Boehringer Ingelheim said they will jointly initiate early combination trials in breast cancer. The …
Boehringer Ingelheim says Phase III trials for its Ofev slowed progression of fatal lung disease
June 27, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, drug trial, idiopathic pulmonary fibrosis, research
German drugmaker Boehringer Ingelheim said late-stage trials for its Ofev (nintedanib) to treat a fatal lung condition slowed progression of …
Sanofi, Boehringer Ingelheim sign definitive agreements for swap
June 27, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, Financial, Sanofi, business swap, merger and acquisition
French drugmaker Sanofi (Euronext: SAN) and German pharma firm Boehringer Ingelheim have signed a definitive agreement for a business swap announced …
Boehringer Ingelheim names Simone Menne new chief financial officer
June 10, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim
German drugmaker Boehringer Ingelheim has named Simone Menne as its new chief financial officer. The current CFO at Lufthansa will …
FDA approves Lilly/Boehringer Ingelheim type-2 diabetes drug
June 1, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, diabetes, jentadueto, jentadueto xr, lilly, partnership, type 2, type-2
The US Food and Drug Administration (FDA) has approved Jentadueto XR (linagliptin and metformin hydrochloride extended release) tablets for the …
Nice recommends three drugs to treat diabetes
May 25, 2016Research and Development, Sales and Marketing AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, NICE, diabetes
The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …
Horizon to acquire worldwide rights to Boehringer Ingelheim genetic disease drug
May 20, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, actimmune, agreement, horizon, interferon gamma-1b, worldwide rights
Horizon Pharmaceuticals (NASDAQ: HZNP) has entered into a worldwide rights agreement with Boehringer Ingelheim to acquire interferon gamma-1b, which is …
Boehringer Ingelheim says new studies underline efficacy of lung disease drug
May 18, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, lung disease
Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile. The …
Latest content
Five Facts about cardiovascular disease
